054670 — Daehan Nupharm Co Share Price
Last trade - 00:00- KR₩95bn
- KR₩118bn
- KR₩202bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.76 | ||
| Price to Tang. Book | 0.77 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.47 | ||
| EV to EBITDA | 5.19 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 12.49% | ||
| Return on Equity | 13.18% | ||
| Operating Margin | 9.23% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 149,293.35 | 166,586.41 | 197,957.35 | 204,222.61 | 202,186.72 | n/a | n/a | 8.56% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -20.95 | +39.05 | +7.68 | -30.47 | +23.33 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Daehan Nupharm Co Ltd is a Korea-based company principally operates in the pharmaceutical business. The Company is involved in the manufacture and sale of human medicines for hypertension, dyslipidemia and diabetes. The Company is involved in the manufacture and sale of animal medicines, such as animal medicines and nutritional supplements. In addition, the Company is engaged in consignment processing.
Directors
- Wan Jin Lee CHM (61)
- Geon Wu Bae CEO (58)
- Yeong Jun Song VPR (61)
- Ju Ha Lee OTH (51)
- Sang Gyu Noh OTH (53)
- Hu Jang Lee NID (51)
- Hwa Yeong Yun NID (57)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 20th, 1984
- Public Since
- February 26th, 2002
- No. of Shareholders
- 11,688
- No. of Employees
- 397
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 14,035,289
- Address
- 66, Jeyakgongdan 1-gil, Hyangnam-eup, HWASEONG, 18622
- Web
- https://www.dhnp.co.kr
- Phone
- +82 313536141
- Auditors
- Daejoo Accounting Corp.
Upcoming Events for 054670
Similar to 054670
AbClon
Korea Exchange - KOSDAQ
ADBiotech Co
Korea Exchange - KOSDAQ
AHN-GOOK PHARMACEUTICAL Co
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
Aminologics Co
Korea Exchange - KOSDAQ
FAQ
As of Today at 20:10 UTC, shares in Daehan Nupharm Co are trading at KR₩6,800. This share price information is delayed by 15 minutes.
Shares in Daehan Nupharm Co last closed at KR₩6,800 and the price had moved by -15.53% over the past 365 days. In terms of relative price strength the Daehan Nupharm Co share price has underperformed the FTSE Developed Asia Pacific Index by -13.64% over the past year.
There is no consensus recommendation for this security.
Find out moreThe Daehan Nupharm Co dividend yield is 1.47% based on the trailing twelve month period.
Last year, Daehan Nupharm Co paid a total dividend of KR₩100, and it currently has a trailing dividend yield of 1.47%. We do not have any data on when Daehan Nupharm Co is to next pay dividends.
We do not have data on when Daehan Nupharm Co is to next pay dividends. The historic dividend yield on Daehan Nupharm Co shares is currently 1.47%.
To buy shares in Daehan Nupharm Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩6,800, shares in Daehan Nupharm Co had a market capitalisation of KR₩95bn.
Here are the trading details for Daehan Nupharm Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 054670
Based on an overall assessment of its quality, value and momentum Daehan Nupharm Co is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Daehan Nupharm Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -9.23%.
As of the last closing price of KR₩6,800, shares in Daehan Nupharm Co were trading -12.07% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Daehan Nupharm Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩6,800.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Daehan Nupharm Co's management team is headed by:
- Wan Jin Lee - CHM
- Geon Wu Bae - CEO
- Yeong Jun Song - VPR
- Ju Ha Lee - OTH
- Sang Gyu Noh - OTH
- Hu Jang Lee - NID
- Hwa Yeong Yun - NID